Effect of an Extract of Green Tea on Adults With Type 2 Diabetes

Status Completed

Clinical Trial Summary

The objective of this study was to determine if taking an extract of green tea for three months could improve glucose control in adults with diabetes.

Clinical Trial Description

Background: Recent evidence suggests that tea from Camellia Senensis (e.g., green, oolong and black tea) may have a hypoglycemic effect. Objective: We evaluated the ability of an extract of green and black tea to improve glucose control over a three month period using a double blinded randomized multiple dose (either placebo, 375mg or 750mg) study in adults in with Type 2 Diabetes. Patients: The 49 subjects who completed this study were predominantly whites with an average age of 65, a median duration of Diabetes of 6 years, and 80% reported using hypoglycemic medication. Measurements: HbA1c at three months was the primary endpoint. Results: After three months the mean changes in HbA1c were +0.4, +0.3 and +0.5, in the placebo, 375mg and 750mg arms, respectively. The changes were not significantly different between study arms. Limitations: Evaluation of a particular extract that contained components of black teas as well as green tea. Power insufficient to detect changes in HbA1c < 0.5. Conclusions: We did not find a hypoglycemic effect of extract of green tea in adults with Type 2 Diabetes, but cannot rule out the possibility that tea may have a small beneficial effect. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00389350
Study type	Interventional
Source	Dartmouth-Hitchcock Medical Center
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	August 2005
Completion date	June 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05594446` - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed	`NCT03975309` - DHS MIND Metabolomics
Completed	`NCT01855399` - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes	N/A
Completed	`NCT01819129` - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes	Phase 3
Recruiting	`NCT04984226` - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD	Phase 2
Recruiting	`NCT05007990` - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting	`NCT04420936` - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program	N/A
Recruiting	`NCT03549559` - Imaging Histone Deacetylase in the Heart	N/A
Completed	`NCT04903496` - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed	`NCT01437592` - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects	Phase 1
Completed	`NCT01696266` - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed	`NCT04082585` - Total Health Improvement Program Research Project
Completed	`NCT03390179` - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting	`NCT05029804` - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes	N/A
Recruiting	`NCT05294822` - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes	N/A
Completed	`NCT04427982` - Dance and Diabetes/Prediabetes Self-Management	N/A
Completed	`NCT02356848` - STEP UP to Avert Amputation in Diabetes	N/A
Completed	`NCT03292185` - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects	Phase 1
Active, not recruiting	`NCT05477368` - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes	N/A
Completed	`NCT04496401` - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus	Phase 4